CliffBio
biologic

Curosurf

poractant alfa

Loss of exclusivityNovember 2011projected — 12-year biologic exclusivity estimate
CompanyChiesi Usa, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameCurosurf
Active ingredientporactant alfa
Strength240MG/3ML (80MG/ML)
Dosage formSuspension
RouteIntratracheal
ModalityBiologic
FDA approvalNovember 1999
Marketing statusRx

More from Chiesi Usa, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Curosurf patent cliff — loss of exclusivity November 2011 | CliffBio